Eight months after Flagship Ventures launched its biotech to develop drugs based on microorganisms in the human body, Atlas Venture today announced $29 million in financing for its entry into that field. Synlogic was founded last fall by Ankit Mahadevia, a partner at Atlas who had a hand in the launch of two other biotechs incubated at that venture firm, Spero Therapeutics and Rodin Therapeutics.